<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"><url><loc>https://insights.citeline.com/medtech-insight/device-area/ophthalmology/alcon-vs-jj-rivalry-of-edof-cataract-market-heats-up-with-jjs-planned-launch-of-tecnis-puresee-WV2HKV3T65AXZML7JPF5WGMT6I/</loc><lastmod>2026-04-17T22:49:51.384Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:49:51.384Z</news:publication_date><news:title><![CDATA[Alcon Vs J&J: Rivalry Of EDOF Cataract Market Heats Up With J&J’s Planned Launch Of TECNIS Puresee]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/hTV6bDZDfxFcVLyA7GJzy0RmYy4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Y6XC47J4JZF4LHYXWQTEQ6S3HI.jpg</image:loc><image:caption><![CDATA[Later this year, Johnson & Johnson Medtech plans the US debut of TECNIS Puresee lens, an extended depth of focus (EDOF) intraocular lens (IOL) for cataract patients, following last month’s US FDA approval.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/product-reviews/us-advisory-committees/recent-and-upcoming-us-fda-advisory-committee-meetings-BPOIZNTRCJF57DRQSK77MYTCPQ/</loc><lastmod>2026-04-17T22:43:26.098Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:43:26.098Z</news:publication_date><news:title><![CDATA[Recent and Upcoming US FDA Advisory Committee Meetings]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/zK-1qhNmlz4zZcY6O0wKSeyretY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/RGEVRT2KERADXPSY5GK6MDEY7M.jpg</image:loc><image:caption><![CDATA[The FDA's oncologic drugs and pharmacy compounding panels have meetings scheduled.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/podcasts/pink-sheet-podcast-cber-director-candidate-emerges-us-fda-promotes-leucovorin-pathway-ZW5MTTYSL5GF5LJVCI7RYZBHTU/</loc><lastmod>2026-04-17T22:43:09.007Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:43:09.007Z</news:publication_date><news:title><![CDATA[Pink Sheet Podcast: CBER Director Candidate Emerges, US FDA Promotes Leucovorin Pathway]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/Gg_gWrVctvsFBg1CcB-LKDTCOc4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/JVY5PWDGIFNT3GV6SLTK2YSK5I.png</image:loc><image:caption><![CDATA[Will the next CBER director offer more stability to the center and its staff?]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/product-reviews/eu-chmp/msds-oral-pcsk9-inhibitor-for-hypercholesterolemia-among-seven-new-eu-filings-PIND6CEPRZFC3JTLMELBDK5IDA/</loc><lastmod>2026-04-17T22:42:50.532Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:42:50.532Z</news:publication_date><news:title><![CDATA[MSD’s Oral PCSK9 Inhibitor For Hypercholesterolemia Among Seven New EU Filings  ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/tpXnOMhllxImzr90zoaXRmUUgUQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/KFMU4ZHXNVGC7KX37O3AW3J7OQ.jpg</image:loc><image:caption><![CDATA[An oral PCSK9 inhibitor for lowering LDL-C is among the latest EU filings]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/legislation/eu-pharma-legislation-reform/eu-pharma-reform-the-changes-ahead-OVHXI7EOENGARNB5GCQKUAVO6M/</loc><lastmod>2026-04-17T22:42:04.348Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:42:04.348Z</news:publication_date><news:title><![CDATA[EU Pharma Reform: The Changes Ahead]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/sCZw0spLM6yHaotax8eFNz5da6w=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QMBCLFFSBBFNNGJHZEPXH5DY2E.jpg</image:loc><image:caption><![CDATA[The new framework will replace the current pharma legislation]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/after-layoffs-hhs-plans-12000-new-hires-aligned-with-trump-administration-priorities-MKX6AZ5RRRA4LK2L2N3M2EGM3A/</loc><lastmod>2026-04-17T22:41:45.39Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:41:45.39Z</news:publication_date><news:title><![CDATA[After Layoffs, HHS Plans 12,000 New Hires Aligned With Trump Administration Priorities]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/mxJCr5YcteCs2JfGEsn5srKpnFU=/cloudfront-us-east-1.images.arcpublishing.com/norstella/JNPSK36BFRDBFEIMR4RREH6REU.jpg</image:loc><image:caption><![CDATA[The FDA FY 2027 budget request indicates staffing levels largely similar to the previous year's enacted budget.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/cnpv-for-life-lillys-foundayo-filing-plans-suggest-voucher-can-span-indications-3ZGTODRCZ5EFZB52CQVMNRABWU/</loc><lastmod>2026-04-17T22:41:35.948Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:41:35.948Z</news:publication_date><news:title><![CDATA[CNPV For Life? Lilly’s Foundayo Filing Plans Suggest Voucher Can Span Indications]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/42_GB8PaZ6q5TitZlfpKgpWPMFw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/KOMKYJ7LMVCZ5GL2KQ3XDD335I.jpg</image:loc><image:caption><![CDATA[Whether a CNPV can span multiple indications is unclear.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/uk-turns-a-corner-on-clinical-trial-set-up-times-but-low-recruitment-still-a-concern-VA7SBSGEE5CDTJBNZRJXOE5OYA/</loc><lastmod>2026-04-17T22:41:24.164Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:41:24.164Z</news:publication_date><news:title><![CDATA[UK ‘Turns A Corner’ On Clinical Trial Set-Up Times But Low Recruitment Still A Concern]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/55q67pfB51yXvKDMj_7h2_k6Sgo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HBKTXWM2KZAYRALFCFKQFHSUZQ.jpg</image:loc><image:caption><![CDATA[UK Says Its 150-Day Clinical Trial Set Up Target Is A Milestone, Not The Finish Line]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/beauty/business/marketing-and-advertising/personal-care-brands-serve-up-spring-campaigns-with-sponsorships-partners-6CL2455A2RCS7KDWG46OEZFC44/</loc><lastmod>2026-04-17T22:14:48.021Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T22:14:48.021Z</news:publication_date><news:title><![CDATA[Personal Care Brands Serve Up Spring Campaigns With Sponsorships, Partners]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/Dd7R_62ybPqDOijIZ1i0YKTcynM=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BW3JDPYO2NHSBHBZFHCISA6OD4.jpg</image:loc><image:caption><![CDATA[La Roche-Posay's 'Shadow Sponsor' campaign to encourage sun protection]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/legalandip/lupin-follows-sandoz-sun-in-antitrust-suit-settlement-30m-for-humana-XUQC7QPY7NCHHANDFIUT57Z6WQ/</loc><lastmod>2026-04-17T21:26:11.895Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T21:26:11.895Z</news:publication_date><news:title><![CDATA[Lupin Follows Sandoz, Sun In Antitrust Suit Settlement; $30m For Humana]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/Qw8fKf3ie5S6CM-W5cqBuSrsuBk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/SBMOJ7GT5NBDPKCHF3JJI2ESCI.jpg</image:loc><image:caption><![CDATA[Lupin Has Entered A Settlement With Humana In The US]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-oricell-terremoto-neomorph-raise-venture-mega-rounds-W43TIDO6NZHAXHOJBCU6GR2F3Y/</loc><lastmod>2026-04-17T21:25:42.963Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T21:25:42.963Z</news:publication_date><news:title><![CDATA[Finance Watch: Oricell, Terremoto, Neomorph Raise Venture Mega-Rounds]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/cInTrHhf4lm96TCzMQLN0bLTTRI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/SDNUC6JU3VLANCGYXXII3MD4RM.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/advanced-therapies/gene-therapies/meiragtx-brings-rare-eye-disease-gene-therapy-back-home-5FSEXSKIGNDJ3NKWYHBNP3GUTE/</loc><lastmod>2026-04-17T21:23:46.589Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T21:23:46.589Z</news:publication_date><news:title><![CDATA[MeiraGTx Brings Rare Eye Disease Gene Therapy Back Home]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/l_N3I4WWePrM-fDJmkLYmiRVUtA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BL7SGYWNTJJRVM6J3WQ2LAOIY4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/deals/deal-watch/ucb-looks-to-bolster-its-epilepsy-pipeline-with-neurona-buyout-Z677AOABDJGG7IKYTKZNPNIVUE/</loc><lastmod>2026-04-17T21:23:16.308Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T21:23:16.308Z</news:publication_date><news:title><![CDATA[UCB Looks To Bolster Its Epilepsy Pipeline With Neurona Buyout]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/q4wJd1ALhCJuzFBi3H_jiLlOywE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/47PO2BXDRBB7BLCCOSDLMJHQSA.jpg</image:loc><image:caption><![CDATA[UCB makes its third epilepsy-related acquisition this decade]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/kailera-ipo-is-biggest-so-far-in-2026-may-become-biopharmas-largest-in-the-us-EMY324OYS5H4TEBSZJO36RJIBI/</loc><lastmod>2026-04-17T21:22:57.139Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T21:22:57.139Z</news:publication_date><news:title><![CDATA[Kailera IPO Is Biggest So Far In 2026, May Become Biopharma’s Largest In The US]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/4ltNjJ3KC3q2rkQm8Qxkhc9gaIA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/MKBAILBCJ5BJFJP6XNRPZXW7ME.jpg</image:loc><image:caption><![CDATA[At least three more companies may soon go public, taking advantage of the recent biopharma bull market]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/business/earnings/abbott-trims-earnings-guidance-on-exact-sciences-deal-but-maintains-sales-outlook-WBFJ76V5OVCUJHLQA5YOMMDWKA/</loc><lastmod>2026-04-17T19:55:13.67Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T19:55:13.67Z</news:publication_date><news:title><![CDATA[Abbott Trims Earnings Guidance On Exact Sciences Deal But Maintains Sales Outlook]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/NefXSkfr4t_qjXFhG0w2EWzXEkY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/VTNZHXIHMFEBFEJDAOPH2JHIMY.jpg</image:loc><image:caption><![CDATA[The company maintained its full-year 2026 sales growth outlook of 6.5% to 7.5% on a comparable basis – a measure that now includes the full-year sales of Exact Sciences in both the prior and current year. Picture Courtesy: Shutterstock]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/legalandip/hikma-hits-back-over-amarins-strawman-induced-infringement-claims-PSI5LAMDUZGFHDCTQKJY2BBAPY/</loc><lastmod>2026-04-17T15:08:44.537Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T15:08:44.537Z</news:publication_date><news:title><![CDATA[Hikma Hits Back Over Amarin’s ‘Strawman’ Induced Infringement Claims]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/bBXccB-MCD9lyYsjYPUnOzpDNAc=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Y7J3VBNZKZCIBNQCSW5WH3364E.jpg</image:loc><image:caption><![CDATA[Hikma says that Amarin’s latest argument relies on “strawman assertions”]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/leadership/us-consumer-health-executive-moves-crnradicle-award-designs-for-health-gimme-seaweed-more-23VWUCYMDBGTZHGA2RDC2BBS54/</loc><lastmod>2026-04-17T14:54:34.985Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T14:54:34.985Z</news:publication_date><news:title><![CDATA[US Consumer Health Executive Moves: CRN/Radicle Award, Designs For Health, Gimme Seaweed, More]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/fNNZZuQsqn25UmkgLw0I8ovBTzc=/cloudfront-us-east-1.images.arcpublishing.com/norstella/W7HD3ITXPFBCDGOQUZMMALAJ44.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/in-vivo/innovation/how-an-italian-ocular-aav-innovator-is-bucking-the-trend-in-gene-therapy-63OPEMWE5ZFPFDYCTUXVGHSRMU/</loc><lastmod>2026-04-17T14:46:47.435Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T14:46:47.435Z</news:publication_date><news:title><![CDATA[How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/l_N3I4WWePrM-fDJmkLYmiRVUtA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BL7SGYWNTJJRVM6J3WQ2LAOIY4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/business/deals/mabwell-finds-a-denosumab-biosimilar-partner-in-malaysia-AIHCZR4ZH5H7BEIG3YVEGE2SCU/</loc><lastmod>2026-04-17T14:39:48.019Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T14:39:48.019Z</news:publication_date><news:title><![CDATA[Mabwell Finds A Denosumab Biosimilar Partner In Malaysia]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/fTTlizLdNgy-Hk4TO0rD_O6nRSI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HETPJMCVFNHDFLEGA23RNT5HAY.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/legislation/why-india-is-considering-the-essential-commodities-act-for-pharma-amid-iran-war-E2K4C6TO7FEYHNUTQREDWYJSRI/</loc><lastmod>2026-04-17T14:13:37.425Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T14:13:37.425Z</news:publication_date><news:title><![CDATA[Why India Is Considering The Essential Commodities Act For Pharma Amid Iran War]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/TJtdgk40utzmVNfAaEEtBxxktRQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YIGANQK24FFZNK5JKFOJEH7IVM.jpg</image:loc><image:caption><![CDATA[Indian Pharma Is Suffering Repercussions Of The US-Israel Coalition's Attack On Iran]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/prolonged-iran-ports-blockade-risks-drug-shortages-wider-supply-chain-woes-OVV2Q5N5RBFARHDE44FPU6XK5A/</loc><lastmod>2026-04-17T14:10:45.588Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T14:10:45.588Z</news:publication_date><news:title><![CDATA[Prolonged Iran Ports Blockade Risks Drug Shortages, Wider Supply Chain Woes]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/t2uGrXbrImnkjA2XhokAhWNJiUY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7PWBKJNARRBJJGPSUZRTV5LACQ.jpg</image:loc><image:caption><![CDATA[Pharma's Supply Chain Woes Could Expand If Freight Disruptions Continue]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-market-struggles-on-iran-war-jobs-data-impacting-biopharma-stocks-3TP24YPCHZH5JNHLEXEBVSIFYY/</loc><lastmod>2026-04-17T13:08:42.597Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:08:42.597Z</news:publication_date><news:title><![CDATA[Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/QP0XsTOKIkbEiMw2sxA1vTD-XIs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UUPCCTOSUNI7ZKUU3DO7RIZNHI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-volatility-impacts-ipos-in-the-us-but-biopharma-is-a-standout-SG5LQH7FXVAH5LCDMQK3NYSNKY/</loc><lastmod>2026-04-17T13:07:59.497Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:07:59.497Z</news:publication_date><news:title><![CDATA[Finance Watch: Volatility Impacts IPOs In The US, But Biopharma Is A Standout ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/QP0XsTOKIkbEiMw2sxA1vTD-XIs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UUPCCTOSUNI7ZKUU3DO7RIZNHI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/supply-chain/amid-iran-war-india-tries-to-keep-lights-on-with-duty-cuts-PMW77UO2HZH4JEFN2ADJJ4PIZU/</loc><lastmod>2026-04-17T13:07:32.768Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:07:32.768Z</news:publication_date><news:title><![CDATA[Amid Iran War, India Tries To Keep Lights On With Duty Cuts]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/BegAK9cO331jGHha6kUvgqh8PDg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QAVEVFLU7BH3ZGD3F42E7X3HPE.jpg</image:loc><image:caption><![CDATA[Freight Rates, Input Costs Higher For Pharma Post Iran War]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/earnings/az-optimistic-on-japan-prospects-despite-pricing-loe-challenges-DKBVZ6JYTRCDHKA2U33Y7Z7AMI/</loc><lastmod>2026-04-17T13:06:38.644Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:06:38.644Z</news:publication_date><news:title><![CDATA[AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/ooWRRRuAysoqCsb99POftf5loLY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/MX66A5YKL5BDHLPGBXBTQC22SA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/supply-chain/prolonged-us-blockade-of-iran-ports-risks-drug-shortages-wider-supply-chain-woes-SEMZ4LNEPVA63KV7XAUFT6VCJY/</loc><lastmod>2026-04-17T13:06:23.123Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:06:23.123Z</news:publication_date><news:title><![CDATA[Prolonged US Blockade Of Iran Ports Risks Drug Shortages, Wider Supply Chain Woes]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/_ynXHk6n6kXasqPeYEY4TEGwTDQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6B2NLA3LNBDAPKLB4OGCGYCEJI.jpg</image:loc><image:caption><![CDATA[Pharma's Supply Chain Risks Might Widen If US Continues Iran Port Blockade]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/podcasts/japan-q1-roundup-podcast-iran-war-impact-divestments-product-approvals-CXMY6RK6PRCV5MZBXTBTQQ2BEE/</loc><lastmod>2026-04-17T13:05:28.634Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:05:28.634Z</news:publication_date><news:title><![CDATA[Japan Q1 Roundup Podcast: Iran War Impact, Divestments, Product Approvals]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/Se-vDyQZyT8_U2adNrPJLTsD9Lc=/cloudfront-us-east-1.images.arcpublishing.com/norstella/SMDB65DUSVENPKZHFR4ADUX3TY.jpg</image:loc><image:caption><![CDATA[Join Lisa Takagi and Ian Haydock for a roundup of key Q1 developments in Japan]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/policy-and-regulation/regulation/northern-ireland-devices-to-use-eudamed-in-may-K7STPOZ6M5F5NMFQPHQRHOZ6BQ/</loc><lastmod>2026-04-17T13:02:40.66Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T13:02:40.66Z</news:publication_date><news:title><![CDATA[Northern Ireland Devices To Use EUDAMED In May]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/rthj1fHxxcTiSIOnnyr7kWbwNS0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/V7QXWYYNK5GI7IHEFSFJ5FXCSY.png</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/health/rx-to-otc-switch/pagb-hosts-swedish-delegation-to-share-rx-to-otc-and-prevention-best-practice-37A5BG2YUVC5HOQD7K7GXYIDKU/</loc><lastmod>2026-04-17T12:50:18.25Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T12:50:18.25Z</news:publication_date><news:title><![CDATA[PAGB Hosts Swedish Delegation To Share Rx-to-OTC And Prevention Best Practice ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/y9Dvd26P-912gx_GQIpJyoJ3dPQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/ZL5HOQU55NGITCMQAIUI2SXGT4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/products/generics/amneal-builds-scale-in-us-drug-device-respiratory-market-VRHFGXXDONEJ7NLQJJTH3BGE5A/</loc><lastmod>2026-04-17T12:48:55.072Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T12:48:55.072Z</news:publication_date><news:title><![CDATA[Amneal Builds Scale In US Drug-Device Respiratory Market]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/K67WK3Pl6qnXQqHYT71aHWpk8dw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/U4KMU7EVHRNGHLO3BRXFYYWDRM.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/policy-and-regulation/us-fda/former-cdrh-diagnostics-lead-deputy-fda-commissioner-tapped-for-hhs-senior-counselor-role-GNHEGKARRFGIHG4FAVPZPAWE6E/</loc><lastmod>2026-04-17T12:26:55.364Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T12:26:55.364Z</news:publication_date><news:title><![CDATA[Former CDRH Diagnostics Lead, Deputy FDA Commissioner Tapped For HHS Senior Counselor Role]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/VNvqvYK1A2eUcDfaqsAeCSLQhSs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/GX7HH2UZNJLHFPJS4O3MEIIZJY.jpg</image:loc><image:caption><![CDATA[FDA Principal Deputy Commissioner Sara Brenner was named senior counselor for public health at the US Department of Health and Human Services.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/regulatory-trackers/european-performance-tracker/eu-filings</loc><lastmod>2026-04-17T11:10:14.61Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T11:10:14.61Z</news:publication_date><news:title><![CDATA[EU Filings]]></news:title></news:news></url><url><loc>https://insights.citeline.com/generics-bulletin/business/deals/mochida-chases-gap-in-japanese-ivf-biosimilars-ZRCQY7V7MBFXRENYEXYEGVIVE4/</loc><lastmod>2026-04-17T10:45:41.548Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T10:45:41.548Z</news:publication_date><news:title><![CDATA[Mochida Chases Gap In Japanese IVF Biosimilars]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/sxp3SdRfo5D4rFcQpKvko4asL8E=/cloudfront-us-east-1.images.arcpublishing.com/norstella/3JDSJGV2BJARXILPMB2P3K4RQE.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/r-and-d/clinical-trials/freya-lines-up-fb301-phase-ii-push-after-promising-early-stage-data-2GYLRW5ONBF57FHYAXSCCHO5X4/</loc><lastmod>2026-04-17T08:59:36.057Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T08:59:36.057Z</news:publication_date><news:title><![CDATA[Freya Lines Up FB301 Phase II Push After Promising Early Stage Data]]></news:title><news:keywords><![CDATA[Clinical Trials,IVF,Women's Health]]></news:keywords></news:news><image:image><image:loc>https://insights.citeline.com/resizer/npqTciVwzRV6IOUQXu4Cg9VW3jo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/4SRSRV5MBBHQDEZ3PU33JOJPR4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/geography/asia/japan/japan-q1-roundup-podcast-iran-war-impact-divestments-product-approvals-P2KZDZYWFVGS5GEZ3CCGRKPUNE/</loc><lastmod>2026-04-17T05:13:45.282Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T05:13:45.282Z</news:publication_date><news:title><![CDATA[Japan Q1 Roundup Podcast: Iran War Impact, Divestments, Product Approvals ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/Gg_gWrVctvsFBg1CcB-LKDTCOc4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/JVY5PWDGIFNT3GV6SLTK2YSK5I.png</image:loc><image:caption><![CDATA[Audio roundup of key Japan biopharma events over the first few months of 2026 ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/government-payers/japan-pricing-roundup-rapid-idvynso-reimbursement-cea-cut-for-briviact-TDODBRQRTFACVPS42JIFWWGY3Y/</loc><lastmod>2026-04-17T00:40:22.814Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:40:22.814Z</news:publication_date><news:title><![CDATA[Japan Pricing Roundup: Rapid Idvynso Reimbursement, CEA Cut For Briviact]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/ejFLYczeavA-yKSS3GyxdZH-iZI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YHQGZMONVFE37OA2UGA7X2FGL4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/companies/clemann-group-sas</loc><lastmod>2026-04-17T00:13:38.446Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:38.446Z</news:publication_date><news:title><![CDATA[CLEMANN GROUP, SAS]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/immupharma-biotech-sas</loc><lastmod>2026-04-17T00:13:36.645Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:36.645Z</news:publication_date><news:title><![CDATA[ImmuPharma Biotech SAS]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/cunde-medical-technology-co-ltd</loc><lastmod>2026-04-17T00:13:32.625Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:32.625Z</news:publication_date><news:title><![CDATA[Cunde Medical Technology Co Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/moogene-medi-co-ltd</loc><lastmod>2026-04-17T00:13:28.477Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:28.477Z</news:publication_date><news:title><![CDATA[Moogene Medi co Ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/chempartner-pharmatech-co-ltd</loc><lastmod>2026-04-17T00:13:24.401Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:24.401Z</news:publication_date><news:title><![CDATA[ChemPartner PharmaTech Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/beijing-houmzen-pharmaceutical-technology-co-ltd</loc><lastmod>2026-04-17T00:13:20.498Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:20.498Z</news:publication_date><news:title><![CDATA[Beijing Houmzen Pharmaceutical Technology Co., Ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/neurofit</loc><lastmod>2026-04-17T00:13:14.568Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:14.568Z</news:publication_date><news:title><![CDATA[Neurofit]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/robotimize-pte-ltd</loc><lastmod>2026-04-17T00:13:10.097Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:10.097Z</news:publication_date><news:title><![CDATA[Robotimize Pte. Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-celliver-biotechnology-co-ltd</loc><lastmod>2026-04-17T00:13:06.118Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:06.118Z</news:publication_date><news:title><![CDATA[Shanghai Celliver Biotechnology Co. Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/kupando-gmbh</loc><lastmod>2026-04-17T00:13:02.223Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:02.223Z</news:publication_date><news:title><![CDATA[Kupando GmbH]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/endolipid-therapeutics</loc><lastmod>2026-04-17T00:13:00.262Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:13:00.262Z</news:publication_date><news:title><![CDATA[Endolipid Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/pharmgen-science-inc</loc><lastmod>2026-04-17T00:12:56.161Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:56.161Z</news:publication_date><news:title><![CDATA[PharmGen Science, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/anxo-pharmaceutical-co-ltd</loc><lastmod>2026-04-17T00:12:51.992Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:51.992Z</news:publication_date><news:title><![CDATA[Anxo Pharmaceutical Co. Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/university-of-exeter</loc><lastmod>2026-04-17T00:12:47.981Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:47.981Z</news:publication_date><news:title><![CDATA[University of Exeter]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/artivila-therapeutics</loc><lastmod>2026-04-17T00:12:44.025Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:44.025Z</news:publication_date><news:title><![CDATA[Artivila Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/pinnacle-medicines</loc><lastmod>2026-04-17T00:12:40.14Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:40.14Z</news:publication_date><news:title><![CDATA[Pinnacle Medicines]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/eos-senolytix-inc</loc><lastmod>2026-04-17T00:12:36.045Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:36.045Z</news:publication_date><news:title><![CDATA[Eos SENOLYTIX, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/biozen-limited</loc><lastmod>2026-04-17T00:12:31.897Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:31.897Z</news:publication_date><news:title><![CDATA[BioZen Limited]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/spliceor-therapeutics</loc><lastmod>2026-04-17T00:12:28.238Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:28.238Z</news:publication_date><news:title><![CDATA[Spliceor Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/es-therapeutics-australia</loc><lastmod>2026-04-17T00:12:24.029Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:24.029Z</news:publication_date><news:title><![CDATA[ES Therapeutics Australia]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shijiazhuang-no4-pharmaceutical-co</loc><lastmod>2026-04-17T00:12:19.83Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:19.83Z</news:publication_date><news:title><![CDATA[Shijiazhuang No.4 Pharmaceutical Co.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/neurothera-labs-inc</loc><lastmod>2026-04-17T00:12:11.661Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:11.661Z</news:publication_date><news:title><![CDATA[Neurothera Labs Inc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/curatis-ag</loc><lastmod>2026-04-17T00:12:04.013Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:12:04.013Z</news:publication_date><news:title><![CDATA[Curatis AG]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/sichuan-yanyang-biotechnology-co-ltd</loc><lastmod>2026-04-17T00:11:59.858Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:59.858Z</news:publication_date><news:title><![CDATA[Sichuan Yanyang Biotechnology Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/parr-bio</loc><lastmod>2026-04-17T00:11:53.759Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:53.759Z</news:publication_date><news:title><![CDATA[Parr Bio]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/sumitomo-bakelite-group</loc><lastmod>2026-04-17T00:11:49.843Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:49.843Z</news:publication_date><news:title><![CDATA[Sumitomo Bakelite Group]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/renascience-inc</loc><lastmod>2026-04-17T00:11:47.656Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:47.656Z</news:publication_date><news:title><![CDATA[Renascience Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/genemagic-biosciences</loc><lastmod>2026-04-17T00:11:40.116Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:40.116Z</news:publication_date><news:title><![CDATA[Genemagic Biosciences]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/ouro-medicines</loc><lastmod>2026-04-17T00:11:35.556Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:35.556Z</news:publication_date><news:title><![CDATA[Ouro Medicines]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/fluid-biomed</loc><lastmod>2026-04-17T00:11:31.553Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:31.553Z</news:publication_date><news:title><![CDATA[Fluid Biomed]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/fastwave-medical-inc</loc><lastmod>2026-04-17T00:11:27.571Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:27.571Z</news:publication_date><news:title><![CDATA[FastWave Medical Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/fivephusion</loc><lastmod>2026-04-17T00:11:23.65Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:23.65Z</news:publication_date><news:title><![CDATA[FivepHusion]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-reinovax-biologics-co-ltd</loc><lastmod>2026-04-17T00:11:19.659Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:19.659Z</news:publication_date><news:title><![CDATA[Shanghai Reinovax Biologics Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/theialife</loc><lastmod>2026-04-17T00:11:07.443Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:07.443Z</news:publication_date><news:title><![CDATA[Theialife Inc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/smsbiotech</loc><lastmod>2026-04-17T00:11:05.342Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:05.342Z</news:publication_date><news:title><![CDATA[SMSbiotech]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/glucomodicum</loc><lastmod>2026-04-17T00:11:03.396Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:03.396Z</news:publication_date><news:title><![CDATA[GlucoModicum]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/glioblastoma-foundation-inc</loc><lastmod>2026-04-17T00:11:01.376Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:11:01.376Z</news:publication_date><news:title><![CDATA[Glioblastoma Foundation Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/synnovation-therapeutics</loc><lastmod>2026-04-17T00:10:59.284Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:59.284Z</news:publication_date><news:title><![CDATA[Synnovation Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/superluminal-medicines-inc</loc><lastmod>2026-04-17T00:10:57.133Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:57.133Z</news:publication_date><news:title><![CDATA[Superluminal Medicines Inc. ]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/imbioray-hangzhou-biomedicine-co-ltd</loc><lastmod>2026-04-17T00:10:53.266Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:53.266Z</news:publication_date><news:title><![CDATA[Imbioray (Hangzhou) Biomedicine Co. Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/piramal-pharma-ltd</loc><lastmod>2026-04-17T00:10:49.146Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:49.146Z</news:publication_date><news:title><![CDATA[Piramal Pharma Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/diamante-srl</loc><lastmod>2026-04-17T00:10:45.026Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:45.026Z</news:publication_date><news:title><![CDATA[Diamante S.r.l.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/grunenthal-meds</loc><lastmod>2026-04-17T00:10:41.157Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:41.157Z</news:publication_date><news:title><![CDATA[Grünenthal Meds]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/valentech-pharma-colombia-sas</loc><lastmod>2026-04-17T00:10:36.974Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:36.974Z</news:publication_date><news:title><![CDATA[Valentech Pharma Colombia SAS]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/sk-bioscience-co-ltd</loc><lastmod>2026-04-17T00:10:28.986Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:28.986Z</news:publication_date><news:title><![CDATA[SK bioscience Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/ningbo-krka-menovo-pharmaceutical-co-ltd</loc><lastmod>2026-04-17T00:10:25.048Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:25.048Z</news:publication_date><news:title><![CDATA[Ningbo Krka Menovo Pharmaceutical Co., Ltd. ]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/turn-biotechnologies-inc</loc><lastmod>2026-04-17T00:10:20.929Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:20.929Z</news:publication_date><news:title><![CDATA[Turn Biotechnologies, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/essential-pharma</loc><lastmod>2026-04-17T00:10:16.781Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:16.781Z</news:publication_date><news:title><![CDATA[Essential Pharma Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/aardvark-therapeutics-inc</loc><lastmod>2026-04-17T00:10:12.902Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:12.902Z</news:publication_date><news:title><![CDATA[Aardvark Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/protagenic-therapeutics-inc</loc><lastmod>2026-04-17T00:10:08.862Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:08.862Z</news:publication_date><news:title><![CDATA[Protagenic Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/i2o-therapeutics-inc</loc><lastmod>2026-04-17T00:10:05.032Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:05.032Z</news:publication_date><news:title><![CDATA[i2O Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shasqi-inc</loc><lastmod>2026-04-17T00:10:00.656Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:10:00.656Z</news:publication_date><news:title><![CDATA[Shasqi, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-zj-bio-tech-co-ltd</loc><lastmod>2026-04-17T00:09:56.63Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:56.63Z</news:publication_date><news:title><![CDATA[Shanghai ZJ Bio-Tech Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/stcube-inc</loc><lastmod>2026-04-17T00:09:52.654Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:52.654Z</news:publication_date><news:title><![CDATA[STCube, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/reig-jofre</loc><lastmod>2026-04-17T00:09:44.573Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:44.573Z</news:publication_date><news:title><![CDATA[Reig Jofre]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/chengdu-sino-strong-pharmaceutical-co-ltd</loc><lastmod>2026-04-17T00:09:40.522Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:40.522Z</news:publication_date><news:title><![CDATA[Chengdu Sino-Strong Pharmaceutical Co Ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/beijing-strong-biotechnologies-inc</loc><lastmod>2026-04-17T00:09:29.495Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:29.495Z</news:publication_date><news:title><![CDATA[Beijing Strong Biotechnologies, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/twi-biotechnology-inc</loc><lastmod>2026-04-17T00:09:23.551Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:23.551Z</news:publication_date><news:title><![CDATA[TWi Biotechnology Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/xiamen-tebao-biotechnology-co-ltd</loc><lastmod>2026-04-17T00:09:17.565Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:17.565Z</news:publication_date><news:title><![CDATA[Xiamen Amoytop Biotech Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/tabuk-pharmaceutical-manufacturing-co</loc><lastmod>2026-04-17T00:09:05.553Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:05.553Z</news:publication_date><news:title><![CDATA[Tabuk Pharmaceutical Manufacturing Co.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/natco-pharma-limited</loc><lastmod>2026-04-17T00:09:02.455Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:09:02.455Z</news:publication_date><news:title><![CDATA[Natco Pharma Limited]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-affinity-biopharmaceutical-co-ltd</loc><lastmod>2026-04-17T00:08:59.209Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:59.209Z</news:publication_date><news:title><![CDATA[Shanghai Affinity Biopharmaceutical Co., Ltd.,]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/nikon-corporation</loc><lastmod>2026-04-17T00:08:53.263Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:53.263Z</news:publication_date><news:title><![CDATA[Nikon Corporation]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/university-of-otago</loc><lastmod>2026-04-17T00:08:47.295Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:47.295Z</news:publication_date><news:title><![CDATA[University of Otago]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/mcgill-university</loc><lastmod>2026-04-17T00:08:41.183Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:41.183Z</news:publication_date><news:title><![CDATA[McGill University]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/university-of-leicester</loc><lastmod>2026-04-17T00:08:35.363Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:35.363Z</news:publication_date><news:title><![CDATA[University of Leicester]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/queens-university</loc><lastmod>2026-04-17T00:08:29.155Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:29.155Z</news:publication_date><news:title><![CDATA[Queen's University]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/university-of-miami</loc><lastmod>2026-04-17T00:08:23.541Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:23.541Z</news:publication_date><news:title><![CDATA[University of Miami]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/redwood-pharma-ab</loc><lastmod>2026-04-17T00:08:17.133Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:17.133Z</news:publication_date><news:title><![CDATA[Redwood Pharma AB]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/acepodia-inc</loc><lastmod>2026-04-17T00:08:11.163Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:11.163Z</news:publication_date><news:title><![CDATA[Acepodia, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/kowa-pharmaceuticals-america-inc</loc><lastmod>2026-04-17T00:08:05.133Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:08:05.133Z</news:publication_date><news:title><![CDATA[Kowa Pharmaceuticals America, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/akrikhin</loc><lastmod>2026-04-17T00:07:59.008Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:59.008Z</news:publication_date><news:title><![CDATA[Akrikhin ]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/generation-bio-co</loc><lastmod>2026-04-17T00:07:52.952Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:52.952Z</news:publication_date><news:title><![CDATA[Generation Bio Co.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/adagene-inc</loc><lastmod>2026-04-17T00:07:46.987Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:46.987Z</news:publication_date><news:title><![CDATA[Adagene Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/auransa-inc</loc><lastmod>2026-04-17T00:07:22.75Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:22.75Z</news:publication_date><news:title><![CDATA[Auransa, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/equillium-inc</loc><lastmod>2026-04-17T00:07:16.808Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:16.808Z</news:publication_date><news:title><![CDATA[Equillium, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/episurf-medical-ab</loc><lastmod>2026-04-17T00:07:10.734Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:10.734Z</news:publication_date><news:title><![CDATA[Episurf Medical AB]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/concarlo-holdings-llc</loc><lastmod>2026-04-17T00:07:04.89Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:07:04.89Z</news:publication_date><news:title><![CDATA[Concarlo Holdings, LLC]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/applied-therapeutics-inc</loc><lastmod>2026-04-17T00:06:58.641Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:58.641Z</news:publication_date><news:title><![CDATA[Applied Therapeutics Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/context-therapeutics-inc</loc><lastmod>2026-04-17T00:06:52.9Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:52.9Z</news:publication_date><news:title><![CDATA[Context Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/hightide-therapeutics-inc</loc><lastmod>2026-04-17T00:06:46.637Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:46.637Z</news:publication_date><news:title><![CDATA[HighTide Biopharma Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/biomx-inc</loc><lastmod>2026-04-17T00:06:40.772Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:40.772Z</news:publication_date><news:title><![CDATA[BiomX Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/avanos-medical-inc</loc><lastmod>2026-04-17T00:06:34.672Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:34.672Z</news:publication_date><news:title><![CDATA[Avanos Medical, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/encellin-inc</loc><lastmod>2026-04-17T00:06:28.389Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:28.389Z</news:publication_date><news:title><![CDATA[Encellin, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/glucotrack-inc</loc><lastmod>2026-04-17T00:06:22.541Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:22.541Z</news:publication_date><news:title><![CDATA[Glucotrack, Inc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/gan-lee-pharmaceuticals</loc><lastmod>2026-04-17T00:06:16.545Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:16.545Z</news:publication_date><news:title><![CDATA[Gan & Lee Pharmaceuticals]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/simon-fraser-university</loc><lastmod>2026-04-17T00:06:10.402Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:10.402Z</news:publication_date><news:title><![CDATA[Simon Fraser University]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/alx-oncology-inc</loc><lastmod>2026-04-17T00:06:04.802Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:06:04.802Z</news:publication_date><news:title><![CDATA[ALX Oncology, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/cleveland-clinic</loc><lastmod>2026-04-17T00:05:46.446Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:46.446Z</news:publication_date><news:title><![CDATA[Cleveland Clinic]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/seres-therapeutics-inc</loc><lastmod>2026-04-17T00:05:40.227Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:40.227Z</news:publication_date><news:title><![CDATA[Seres Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/hemogenyx-pharmaceuticals-plc</loc><lastmod>2026-04-17T00:05:28.394Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:28.394Z</news:publication_date><news:title><![CDATA[Hemogenyx Pharmaceuticals plc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-pharmaceutical-group-co-ltd</loc><lastmod>2026-04-17T00:05:22.221Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:22.221Z</news:publication_date><news:title><![CDATA[Shanghai Pharmaceuticals Holding Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/inhibrx-inc</loc><lastmod>2026-04-17T00:05:16.257Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:16.257Z</news:publication_date><news:title><![CDATA[Inhibrx, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/heartflow-inc</loc><lastmod>2026-04-17T00:05:10.236Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:10.236Z</news:publication_date><news:title><![CDATA[HeartFlow, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/chiesi-farmaceutici-spa</loc><lastmod>2026-04-17T00:05:01.158Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:05:01.158Z</news:publication_date><news:title><![CDATA[Chiesi Farmaceutici S.p.A.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/ose-immunotherapeutics</loc><lastmod>2026-04-17T00:04:49.269Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:04:49.269Z</news:publication_date><news:title><![CDATA[OSE Immunotherapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/alaunos-therapeutics-inc</loc><lastmod>2026-04-17T00:04:37.349Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:04:37.349Z</news:publication_date><news:title><![CDATA[Alaunos Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/abeona-therapeutics-inc</loc><lastmod>2026-04-17T00:04:25.155Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:04:25.155Z</news:publication_date><news:title><![CDATA[Abeona Therapeutics Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/akari-therapeutics-plc</loc><lastmod>2026-04-17T00:04:00.862Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:04:00.862Z</news:publication_date><news:title><![CDATA[Akari Therapeutics, Plc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/anteris-technologies-global-corp</loc><lastmod>2026-04-17T00:03:48.869Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:03:48.869Z</news:publication_date><news:title><![CDATA[Anteris Technologies Global Corp.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/oragenics-inc</loc><lastmod>2026-04-17T00:03:36.881Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:03:36.881Z</news:publication_date><news:title><![CDATA[Oragenics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/adimmune-corporation</loc><lastmod>2026-04-17T00:03:24.629Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:03:24.629Z</news:publication_date><news:title><![CDATA[Adimmune Corporation]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/domain-therapeutics-sa</loc><lastmod>2026-04-17T00:03:15.395Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:03:15.395Z</news:publication_date><news:title><![CDATA[Kainova Therapeutics S.A.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/quantum-genomics-corp</loc><lastmod>2026-04-17T00:03:00.687Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:03:00.687Z</news:publication_date><news:title><![CDATA[Quantum Genomics Corp.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/avalo-therapeutics-inc</loc><lastmod>2026-04-17T00:02:48.582Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:02:48.582Z</news:publication_date><news:title><![CDATA[Avalo Therapeutics, Inc. ]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/ab-science-sa</loc><lastmod>2026-04-17T00:02:36.702Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:02:36.702Z</news:publication_date><news:title><![CDATA[AB Science S.A.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/theriva-biologics-inc</loc><lastmod>2026-04-17T00:02:24.549Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:02:24.549Z</news:publication_date><news:title><![CDATA[Theriva Biologics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/teleflex-incorporated</loc><lastmod>2026-04-17T00:02:00.461Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:02:00.461Z</news:publication_date><news:title><![CDATA[Teleflex Incorporated]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/astellas-pharma-inc</loc><lastmod>2026-04-17T00:01:48.687Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:01:48.687Z</news:publication_date><news:title><![CDATA[Astellas Pharma, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/gilead-sciences-inc</loc><lastmod>2026-04-17T00:01:36.677Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-17T00:01:36.677Z</news:publication_date><news:title><![CDATA[Gilead Sciences, Inc.]]></news:title></news:news></url></urlset>